Zentalis Pharmaceuticals, Inc. (ZNTL)
3.80
-0.08
(-2.06%)
USD |
NASDAQ |
Aug 28, 16:00
3.80
0.00 (0.00%)
After-Hours: 20:00
Zentalis Pharmaceuticals Debt to Equity Ratio : 0.2624 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.2624 |
| March 31, 2026 | 0.2116 |
| December 31, 2025 | 0.1831 |
| September 30, 2025 | 0.16 |
| June 30, 2025 | 0.1505 |
| March 31, 2025 | 0.1309 |
| December 31, 2024 | 0.1265 |
| September 30, 2024 | 0.1221 |
| June 30, 2024 | 0.1151 |
| March 31, 2024 | 0.0989 |
| December 31, 2023 | 0.1047 |
| September 30, 2023 | 0.0948 |
| June 30, 2023 | 0.0886 |
| March 31, 2023 | 0.122 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.1091 |
| September 30, 2022 | 0.0052 |
| June 30, 2022 | 0.0037 |
| March 31, 2022 | 0.004 |
| December 31, 2021 | 0.1261 |
| September 30, 2021 | 0.0022 |
| June 30, 2021 | 0.0036 |
| March 31, 2021 | 0.0041 |
| December 31, 2020 | 0.0065 |
| September 30, 2020 | 0.0026 |
| June 30, 2020 | 0.0038 |
| March 31, 2020 | -1.634 |
| December 31, 2019 | 0.0402 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ARS Pharmaceuticals, Inc. | 7.727 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 215.33M |
| Total Liabilities (Quarterly) | 71.68M |
| Shareholders Equity (Quarterly) | 143.65M |
| Current Ratio | 4.818 |
| Net Debt Paydown Yield | 0.06% |